A PDUFA date stock run-up happens because traders buy ahead of a known FDA deadline, not because anything has been approved. The PDUFA date is the FDA’s target date to act on a drug application. The run-up and the decision are separate events, and the filings tell you whether the company is set up to sell stock into either one.
This post covers what the date actually is, why the price action before and after it behaves differently, and a filings checklist you can run on any company with a pending FDA decision before you touch the chart.
In this article
- What is a PDUFA date?
- Why do biotech stocks run up before a PDUFA date?
- Why the PDUFA date stock run-up and the decision are separate events
- The PDUFA date filings checklist
- How do you set price-level alerts instead of chasing?
- Red flags in a small-cap PDUFA run-up
- FAQ
What is a PDUFA date?
A PDUFA date is the goal date by which the FDA has committed to finish reviewing a drug or biologic application, set under the Prescription Drug User Fee Act.
Under PDUFA, drug sponsors pay user fees and the FDA commits to review performance goals in return. Congress reauthorizes the program every five years, and the FDA’s PDUFA page links the current commitment letter that spells out the review timelines.
The short version: a standard review targets roughly 10 months and a priority review roughly 6 months. For new molecular entities and original biologics, that clock starts after a 60-day filing period, so the real wait from submission is longer. If the sponsor submits a major amendment late in the review, the FDA can extend the goal date by three months.
Three things traders often get wrong:
- The FDA generally does not publish the date. The company discloses it, usually in a press release, 10-Q, 10-K or investor deck.
- It is a goal, not an appointment. The FDA can act before it, and the outcome is either an approval or a complete response letter (CRL) listing what still needs fixing.
- A CRL is not always a permanent no, but it usually means more time and more cash before any approval.
Why do biotech stocks run up before a PDUFA date?
Because the date is known, the outcome is binary, and many small-cap biotechs have thin floats that move hard on modest volume. Traders front-run the event, momentum traders chase the front-runners, and the chart starts pricing a hope rather than a fact.
Hypothetical example: a biotech with a $40M market cap discloses a goal date six weeks out. Scanners pick it up, social chatter builds, and the stock climbs 60% over two weeks. Nothing about the drug changed. What changed is who owns the shares and why they bought them.
Why the PDUFA date stock run-up and the decision are separate events
The run-up is a positioning trade. The decision is a fundamental event with a financing problem attached. Treat them as two different trades with two different risk profiles.
Plenty of run-up buyers have no intention of holding through the decision. They sell into the last days before the date to avoid gap risk, which is why some charts fade before the FDA has said anything. Then, on the decision, the company itself often becomes a seller: an approved drug needs money to launch, and a higher share price makes raising it cheaper. We break that pattern down in why biotech stocks drop on good news.
Fockets Terminal data across all the runs it tracks (not biotech only) shows why the filing matters: runs on a priced offering closed down 4.3% on average and 65% faded, while runs on an 8-K closed up 3.5%. Same kind of spike, different filing, different outcome.
Do biotech stocks go up or down after FDA approval?
Both happen. How much was priced in during the run-up, the label the FDA grants, the commercial plan and how badly the company needs cash all matter. A CRL usually means a hard gap down, and the stock may be halted pending news around the announcement. Approval can still sell off if the company prices an offering the same day.
The PDUFA date filings checklist
Run these five checks on EDGAR before you look at a single candle. They tell you how much stock the company can sell, how fast, and how badly it needs to.
| Check | Where to find it | What it tells you |
|---|---|---|
| S-3 status | S-3 filing and the EFFECT notice on EDGAR | Whether the company can sell registered shares quickly |
| Baby shelf limit | Public float on the 10-K cover, current share price, S-3 instructions | The maximum it can raise off the shelf in 12 months |
| Active ATM | Sales agreement in an 8-K, 424B5 prospectus supplement, 10-Q | Whether shares can be dripped into run-up volume |
| Cash runway | Latest 10-Q balance sheet and cash flow statement | How long until it must raise, approval or not |
| Warrant overhang | 10-Q equity note, prior offering 8-Ks and prospectuses | Strike prices where new supply can show up |
1. S-3 status
An effective S-3 shelf lets a company sell registered shares fast, often overnight. Search the ticker on EDGAR for an S-3 and a matching EFFECT notice. If there is none, a raise is slower and messier, though not impossible.
2. The baby shelf limit
Under General Instruction I.B.6 of Form S-3, a company with a public float under $75M can sell no more than one-third of that float off the shelf in any 12-month period. Here is the trap: a run-up raises the public float, which raises the limit.
Hypothetical: public float of $45M means about $15M of capacity. If the run pushes the float above $75M, the cap stops applying. Our baby shelf rule calculation walks through the math, including prior sales that count against the limit.
3. An active ATM
An at-the-market program lets the company sell shares straight into the market through a sales agent. A run-up with heavy volume is the ideal place to use it, and you will not see a press release when it happens. Look for the sales agreement and the 424B5, then check the next 10-Q for shares sold after quarter end. More on the mechanics in ATM offering effect on stock price.
4. Cash runway
Take cash and short-term investments, divide by quarterly operating cash burn, and you get a rough number of quarters left. An approval does not pay for a launch. If the runway is short or the 10-Q carries going concern language, a raise around the decision is close to the default case. Use the cash runway calculation guide to do it properly.
5. Existing warrant overhang
Older offerings often left warrants behind. The 10-Q equity note lists outstanding warrants and exercise prices. If a large block sits just above the current price, a run into that level brings new supply as holders exercise and sell.
How do you set price-level alerts instead of chasing?
Do the checklist first, then mark the levels that matter: the last offering price, big warrant strikes, the point where your plan says you are wrong. Set alerts there and walk away from the screen. If price never gets there, you never had a trade.
The Fockets Terminal lets you set price-level, big-move, unusual-volume and opening-range-break alerts that land in your Discord DMs, and it ties each big move to the filing behind it: offering, 8-K, insider buy or nothing. It is a tool for your plan, not a list of trades to copy.
Decide before the date whether you will hold through the decision at all. A gap on a CRL can blow straight through a stop, so size the position as if the stop does not exist.
Red flags in a small-cap PDUFA run-up
- The goal date is hyped online but you cannot find it in the company’s own filings.
- Heavy volume with no new filing behind it.
- A fresh S-3, ATM or sales agreement filed weeks before the date.
- Paid newsletters quoting confident approval odds with no sources.
- An advisory committee meeting on the FDA calendar that nobody pumping the ticker mentions.
FAQ
How many days before a PDUFA date do biotech stocks run up?
There is no fixed number. Some run for weeks, some only in the final days, some never. Anyone quoting a precise window should show you the data set.
Where can I find upcoming PDUFA dates?
Start with company press releases, 10-Qs and 10-Ks. Free and paid catalyst calendars compile those disclosures, so verify every date against the original filing.
What happens if a PDUFA date is extended?
A major amendment can push the goal date back three months. The stock reaction varies, but the company keeps burning cash during the wait, which makes the runway check even more important.
What is IV crush around a PDUFA date?
Options price in high implied volatility ahead of a binary event. Once the decision is out, implied volatility usually drops, so an option can lose value even if you guessed the direction right.
If you want to see how other traders read these filings in real time, join the free Fockets stock trading Discord. Ask questions, share your own checklist, and learn to do the work yourself.
Keep reading
Disclaimer: This post is for educational purposes only and is not financial advice. Fockets Trading does not make buy or sell recommendations. Trading small caps and biotech stocks carries significant risk, including the loss of your entire investment. Do your own research and size your own risk.
